HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antimicrobial resistance

This article was originally published in The Rose Sheet

Executive Summary

Public meeting to discuss Antimicrobial Resistance Interagency Task Force Annual Report will be held June 26 in Bethesda, Md. CDC, FDA and NIH will provide progress update on "A Public Health Action Plan to Combat Antimicrobial Resistance," which serves as blueprint for activities to address antimicrobial restistance, HHS says in 1May 8 Federal Register notice. Meeting will cover surveillance, prevention and control, research and product development. For more information, contact Vickie Garrett at the Antimicrobial Resistance Director's office (404-639-2603). Evaluation of benefits/risks of incorporating disinfectants and chemicals into consumer products such as soap was included in the action plan, which was unveiled last year (2"The Rose Sheet" Jan. 22, 2001, In Brief)...

You may also be interested in...

Antimicrobial action plan

Evaluation of benefits/risks of incorporating antimicrobial disinfectants or chemicals into consumer products such as soap included in final interdepartmental antimicrobial resistance action plan unveiled by HHS Jan. 18. Although not specified in the final version, a draft released in June said agencies likely will consider whether such products "have any efficacy in reducing infection" and if they "play a role in promoting drug resistance" (1"The Rose Sheet" June 26, 2000, p. 8). Developed by the Task Force on Antimicrobial Resistance, the plan designates priorities, identifies responsible agencies and creates timelines for facilitating surveillance, prevention and control, research and product development to address antimicrobial resistance. CDC, NIH and FDA are leading task force of 10 agencies and departments

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts